Surrogacy Case Study: Prostate Specific Antigen (PSA ... - Isped
Surrogacy Case Study: Prostate Specific Antigen (PSA ... - Isped
Surrogacy Case Study: Prostate Specific Antigen (PSA ... - Isped
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Published <strong>PSA</strong> surrogacy studies<br />
D’Amico<br />
JNCI ’03<br />
Dehnam<br />
Lancet ‘08<br />
Sandler<br />
JCO ’03<br />
Valicenti<br />
IJROBP ’06<br />
D’Amico<br />
J Urol ’05<br />
Newling<br />
JCO ’04<br />
After RP or RT<br />
(cohorts)<br />
After RT+0 or 3 or<br />
6 m ADT (TROG<br />
96.01)<br />
After RT+4 or 24 m<br />
ADT (RTOG 92-02)<br />
After RT+4 or 24 m<br />
ADT (RTOG 92-02)<br />
ADT for <strong>PSA</strong><br />
relapse after RP or<br />
RT (cohorts)<br />
M0 on primary<br />
ADT (EPC trial)<br />
<strong>PSA</strong>-DT PC-surv Prentice<br />
<strong>PSA</strong>-DT<br />
TTBF<br />
PC-surv<br />
Prentice<br />
TTBF PC-surv Prentice<br />
<strong>PSA</strong>-DT PC-surv Prentice<br />
<strong>PSA</strong>-V PC-surv Prentice<br />
T to <strong>PSA</strong><br />
doubling<br />
Clinical<br />
relapse<br />
Meta-analysis<br />
RP=radical prostatectomy, RT=radiotherapy, HT=hormonal therapy, M0=non metastatic,<br />
M1=metastatic, PC-surv=<strong>Prostate</strong> cancer specific survival
Change language